KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Net Income (2016 - 2025)

Historic Net Income for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $251.5 million.

  • Jazz Pharmaceuticals' Net Income rose 1677.3% to $251.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$275.8 million, marking a year-over-year decrease of 15926.84%. This contributed to the annual value of $561.8 million for FY2024, which is 3444.83% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Net Income stood at $251.5 million, which was up 1677.3% from -$718.4 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Net Income registered a high of $251.5 million during Q3 2025, and its lowest value of -$718.4 million during Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' median Net Income value was $53.8 million (recorded in 2022), while the average stood at -$1.7 million.
  • In the last 5 years, Jazz Pharmaceuticals' Net Income plummeted by 64182.59% in 2022 and then surged by 111653.14% in 2023.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Net Income stood at -$32.3 million in 2021, then tumbled by 641.83% to -$240.0 million in 2022, then soared by 139.43% to $94.6 million in 2023, then surged by 102.01% to $191.1 million in 2024, then soared by 31.56% to $251.5 million in 2025.
  • Its last three reported values are $251.5 million in Q3 2025, -$718.4 million for Q2 2025, and $191.1 million during Q4 2024.